J Clin Oncol 30:2248-2255. (c) 2012
by American Society of Clinical Oncology”
“Purpose: To characterize conjunctival cells obtained by brush cytology (BC) and establish short-term cultures.\n\nMethods: Human tarsal and bulbar conjunctival cells were obtained by BC and transported in 3 different media: serum-free medium (DK-SFM) with low [Ca(2+)], 10% fetal bovine serum (FBS) supplemented medium (FBSm10), and 20% FBS-supplemented medium (FBSm20). Recovered cells were counted and initial viability assessed. Flow cytometry established epithelial or immune lineage, viability, apoptosis, check details and cell cycle stage. To establish short-term cultures, tarsal conjunctival cells were seeded onto Permanox (TM) or denuded amniotic membrane (dAM) and cultured in the 3 media. Living adherent cells were assessed on Days 1, 2, and 5 by fluorescence microscopy.\n\nResults: Initial cell recovery was significantly lower with DK-SFM than in the other two culture media. Flow cytometry showed that 3.8 +/- 0.4% of recovered tarsal
cells were CD45+ leukocytes and 67.9 +/- 1.6% were CK7+ secretory epithelial cells. S-phase cells composed 3.5 +/- 0.3% of the recovered tarsal cells and 2.1 +/- 0.2% of the bulbar cells (p=0.0006). Selleck GDC 0068 The percentage of viable, apoptotic, and dead cells was similar for tarsal and bulbar cells. Two different cell populations were observed in both locations. About 24% consisted of smaller, less complex cells with high viability, and the remainder
was composed of larger, more complex cells with poor viability. Significantly more living cells were supported by FBSm10 on the dAM substratum (p=0.011) than by the other media on either dAM or Permanox.\n\nConclusions: Conjunctival BC recovers proliferating cells that can be maintained on dAM in FBSm10 for up to 5 days.”
“OBJECTIVE: The purpose of this study was to examine the association between preeclampsia and cancer incidence.\n\nSTUDY DESIGN: The Jerusalem Perinatal Study is a population-based cohort of all births to 41,206 residents of Western Jerusalem Erastin clinical trial from 1964-76. Cancer incidence to 2004 was assessed by linkage of the cohort with the Israel Cancer Registry. Cox’s proportional hazards models were constructed to estimate the hazard ratio for cancer among women who had had preeclampsia.\n\nRESULTS: Preeclampsia was associated with a 1.23-fold increased risk of cancer at all sites, a 37% increased risk of breast cancer, and more than a doubling of ovarian cancer risk. Analysis by morphologic condition yielded significantly increased risks for malignancies that were classed as cystic mucinous and serous (relative risk, 1.96; 95% CI, 1.00-3.83) and for ductal, lobular, and medullary carcinomas (relative risk, 1.40; 95% CI, 1.07-1.83). No differential association was observed by sex of offspring.